Sign In
Buy NBIX
$175.77
+1.62 (+0.93%)
At Close: Jul 24, 2026
Neurocrine Biosciences Appoints Andrew Ratz, Ph.D., as Chief Technical Operations Officer
04:05pm, Tuesday, 17'th Mar 2026
SAN DIEGO, March 17, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the promotion of Andrew Ratz, Ph.D., to the executive management team as the Chief Technical Opera
CreativeOne Wealth LLC Has $1.10 Million Stock Position in Neurocrine Biosciences, Inc. $NBIX
03:54am, Thursday, 12'th Mar 2026
CreativeOne Wealth LLC lessened its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ: NBIX) by 34.5% during the undefined quarter, according to its most recent disclosure with the SEC. The inst
Neurocrine Biosciences to Present at the Stifel 2026 Virtual CNS Forum
04:01pm, Tuesday, 10'th Mar 2026
SAN DIEGO, March 10, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that members of the management team will participate at the Stifel 2026 Virtual CNS Forum at 4:30
Neurocrine Biosciences, Inc. (NBIX) Presents at Leerink Global Healthcare Conference 2026 Transcript
10:57am, Monday, 09'th Mar 2026
Neurocrine Biosciences, Inc. (NBIX) Presents at Leerink Global Healthcare Conference 2026 Transcript
BetterInvesting™ Magazine Update on Equifax Inc. (NYSE: EFX) and Neurocrine Bio In. (NASDAQ: NBIX)
05:00pm, Friday, 06'th Mar 2026
TROY, Mich., March 6, 2026 /PRNewswire/ -- Equifax Inc.'s recent report has investors wondering if the company's stock is fairly valued.
Focus Partners Advisor Solutions LLC Buys 8,011 Shares of Neurocrine Biosciences, Inc. $NBIX
04:00am, Friday, 06'th Mar 2026
Focus Partners Advisor Solutions LLC raised its position in Neurocrine Biosciences, Inc. (NASDAQ: NBIX) by 152.5% in the undefined quarter, according to its most recent Form 13F filing with the SEC. T
Neurocrine Biosciences, Inc. (NBIX) Presents at TD Cowen 46th Annual Health Care Conference Transcript
02:02pm, Tuesday, 03'rd Mar 2026
Neurocrine Biosciences, Inc. (NBIX) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Neurocrine Biosciences to Present at Upcoming Investor Conferences in March
04:01pm, Tuesday, 24'th Feb 2026
SAN DIEGO, Feb. 24, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that members of the management team will participate at the following investor conferences: TD Cowe
Pre-Market Stock Futures: Futures are trading higher this morning after a dreadful day to start the trading week. Various reasons were cited for the risk-off bias on Monday, but the tariff situation,
New Strong Sell Stocks for February 18th
05:20am, Wednesday, 18'th Feb 2026
COIN, NBIX and UPST have been added to the Zacks Rank #5 (Strong Sell) List on February 18th, 2026.
JPMorgan Chase & Co. Has $664.02 Million Stock Holdings in Neurocrine Biosciences, Inc. $NBIX
04:14am, Wednesday, 18'th Feb 2026
JPMorgan Chase and Co. increased its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ: NBIX) by 11.0% in the undefined quarter, according to its most recent disclosure with the Securities an
Neurocrine Biosciences: Growth Beyond Just Ingrezza
04:18am, Friday, 13'th Feb 2026
Neurocrine Biosciences has successfully diversified beyond Ingrezza, with Crenessity's rapid adoption validating its multi-franchise commercial strategy. NBIX's late-stage neuropsychiatry pipeline, in
Analysts Stay Bullish As Neurocrine Shares Tumble On Disappointing Ingrezza Guidance
02:38pm, Thursday, 12'th Feb 2026
Neurocrine Biosciences Inc (NASDAQ: NBIX) on Wednesday reported fourth-quarter adjusted earnings of $1.88 per share, missing the consensus of $1.89.
Neurocrine Biosciences: Expanding Opportunities, 2026 Will Be Less Exciting
02:16pm, Thursday, 12'th Feb 2026
Neurocrine Biosciences reported largely in-line Q4 results, with better-than-expected Crenessity sales; guidance for 2026 was in-line with published expectations but arguably a bit lackluster. NBIX's
Neurocrine Biosciences, Inc. (NBIX) Q4 2025 Earnings Call Transcript
08:14pm, Wednesday, 11'th Feb 2026
Neurocrine Biosciences, Inc. (NBIX) Q4 2025 Earnings Call Transcript
